Apellis Pharmaceuticals, Inc..
APLS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat disease through the complement system. The company's first approved product is EMPAVELI (pegcetacoplan), an injectable tr...Show More
Better Health for All
-40
Apellis Pharmaceuticals' core business is dedicated to developing therapies for serious and rare diseases, with approved products like EMPAVELI (for PNH) and SYFOVRE (for geographic atrophy).
1
EMPAVELI was the first new class of complement medicine in 15 years (2021),
2
and SYFOVRE achieved over 120% net sales growth year-over-year in 2024.
3
Clinical trials for pegcetacoplan have shown statistically significant improvements in hemoglobin for PNH patients and reduced hemolysis in CAD patients.
4
The company's ApellisAssist program offers financial assistance and free medication to eligible patients, including those with no insurance or limited coverage, and provides compassionate use and early access programs for critically ill patients.
5
However, the company has faced safety concerns, including a voluntary pause in Phase 3 GA trials in 2018 due to non-infectious inflammation in 4 patients,
6
and reported adverse events in clinical trials such as injection site reactions (36.6%), diarrhea (22.0%), and new onset exudation (21% monthly) for pegcetacoplan.
7
More recently, SYFOVRE clinical trials showed increased rates of neovascular AMD (12% monthly, 7% every other month) by Month 24.
8
The company has a Corrective and Preventive Action (CAPA) program for product safety complaints and reported no fatalities, recalls, or FDA enforcement actions in 2021.
9
Apellis provides comprehensive risk disclosures in its 10-K filings
10
and through its EAP & CU Core Principles.
11
The company supports its employees with 100% coverage of medical insurance costs, 10 weeks of paid parental leave, and 24/7 behavioral health support.
12
Apellis also engages in health education through its Administration Demonstration program and digital resources.
13
The company's waste management in 2021 included 6,030 lbs of biological waste treated safely and 170 lbs of hazardous waste treated by a third-party vendor.
14
Fair Money & Economic Opportunity
0
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company.
1
The 'Fair Money & Economic Opportunity' value and its associated KPIs are primarily designed for financial institutions. The company does not offer lending, deposit, or other consumer financial services.
2
Therefore, most KPIs related to APRs, fees, loan books, debt, and financial literacy programs are not applicable to its core business model. The company does not generate or manage customer finance data, nor does it operate financial service access points.
3
While Apellis has patient assistance programs
4
and an employee stock purchase plan,
5
these do not align with the specific quantitative thresholds for financial products or services as defined in the rubric.
Fair Pay & Worker Respect
0
Apellis Pharmaceuticals reported a CEO to median employee pay ratio of 33:1 in 2024.
1
The company's overall employee rating on Glassdoor is 3.4 out of 5 stars, with 58% of employees recommending working there and 74% approving of the CEO.
2
The Compensation and Benefits rating is 2.7 out of 5 stars.
3
The company conducts a formalized company-wide annual employee engagement survey, supplemented by pulse surveys, with results presented to employees and actions taken to improve the employee experience.
4
The company is laying off approximately 25% of its staff, affecting about 225 full-time employees.
5
Additionally, there are plans for an incremental reduction of approximately 40 employees in the ex-U.S. footprint.
6
Apellis states that employee attrition has generally been significantly below market and turnover rates are below industry trends.
7
The company covers 100% of employees’ medical insurance costs, including for dependents, and offers comprehensive health, dental, and vision insurance, along with 24/7 behavioral health support and a Global Employee Assistance Program.
8
The Global Supplier Code of Conduct, effective August 26, 2020, prohibits slave, child, underage, forced, bonded, or indentured labor and states that workplaces must be free of harassment and abuse.
9
No specific data on the percentage of the workforce on temporary or gig contracts is available.
Fair Trade & Ethical Sourcing
0
The provided articles, which include job postings and corporate governance documents, do not contain any specific, quantitative data points related to Apellis Pharmaceuticals' fair trade and ethical sourcing practices. While a Supplier Code of Conduct is mentioned, no metrics on fair trade certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend are available.
1
Honest & Fair Business
-10
Apellis Pharmaceuticals has a formal whistleblower policy, effective June 12, 2025, which protects individuals making good faith reports from retaliation.
1
It includes an anonymous, confidential, 24/7 Ethics and Compliance Hotline.
2
The company filed an Amendment to a previously filed 10-K (Form 10-K/A) on February 29, 2024, for the period ending December 31, 2023.
3
Apellis maintains a formalized Anti-Bribery and Anti-Corruption policy detailed in its Code of Business Conduct and Ethics, with a Compliance Committee overseeing the program, which includes compliance with the Foreign Corrupt Practices Act and the U.K. Bribery Act.
4
All new personnel and contractors receive compliance training.
5
The Compliance Committee is authorized to engage independent legal and other advisors,
6
but there is no specific percentage of ethical claims independently verified.
7
Kind to Animals
-50
Apellis Pharmaceuticals' Global Supplier Code of Conduct states that animal testing should only be performed after considering replacement, reduction, or refinement, and alternatives should be used wherever scientifically valid and acceptable to regulators.
1
The company's experiments used a total of 95 rats across various studies, including 24 male Sprague Dawley rats, 48 female Lewis rats, 5 healthy female Lewis rats, 10 non-MG animals, 20 PTMG animals, and 8 PTMG animals.
2
These experiments were conducted with permission from an Animal Welfare Committee, in accordance with Dutch laws and Maastricht University regulations, and included the use of analgesia.
3
While in vitro techniques like ELISA and RT-qPCR were employed for analysis, the studies primarily relied on animal models.
4
No War, No Weapons
0
No specific, concrete data points were found in the provided articles to assess Apellis Pharmaceuticals, Inc. against the 'No War, No Weapons' ethical value. The articles did not contain information regarding revenue from arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, conflict divestment policies, board oversight of defense-related activities, export end-user certifications, lobbying against arms control, humanitarian procurement compliance, human rights due diligence frequency in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines related to weapons, exposure to controversial weapons, war risk audit results, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, conflict zone procurement, or ethical red lines compliance rates.
1
Planet-Friendly Business
0
Apellis Pharmaceuticals, Inc. lacks publicly available data across all assessed environmental performance indicators. There is no reported information on Scope 1, 2, or 3 emissions, renewable energy consumption, water usage, waste diversion rates, or green building certifications.
1
The company also does not disclose any science-based targets, details on climate-positive initiatives, or supply chain climate transparency.
2
Furthermore, there is no evidence of environmental compliance violations, climate scenario analysis, or stranded asset transparency.
3
The absence of data extends to packaging CO2 reduction, biodiversity efforts, deforestation policies, and climate justice or just transition programs.
4
Respect for Cultures & Communities
0
No evidence available to assess Apellis Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Apellis Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided article focuses on Apellis Pharmaceuticals' overall ESG score and net impact ratio, highlighting positive impacts in areas like Physical Diseases and Creating Knowledge, and negative impacts in Scarce Human Capital and GHG Emissions.
1
However, it explicitly states that no specific quantitative data related to waste diversion, product recyclability, packaging sustainability, or other metrics relevant to zero waste and sustainable product practices is provided.
2
Therefore, no KPIs can be scored based on the available evidence.